Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Related Videos
Jeffery Zonder, MD
Jeffery Zonder, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Eunice Wang, MD
Craig Sauter, MD
Matthew Frank, MD, PhD
Related Content